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Localization of the prostacyclin receptor in human kidney.
Background. Prostacyclin is an important mediator of renal
hemodynamics. Furthermore, recent studies argue for a role of
this arachidonic acid metabolite in the regulation of salt and water
handling in the distal nephron. To gain insight into the network of
prostacyclin signal transduction, we analyzed the intrarenal distri-
bution of the prostacyclin receptor (IP receptor) in adult human
kidney.
Methods. Specific polyclonal antibodies against a synthetic
peptide of the human IP receptor were generated. By means of
immunohistology the localization of IP receptor protein was
studied. The mRNA expression for IP receptor was analyzed by in
situ hybridization using specific cRNA probes.
Results. In human kidney sections both IP receptor-immunore-
active protein and mRNA were expressed in smooth muscle cells
and endothelial cells. Expression of the IP receptor was observed
in glomerular cells, namely mesangial cells, endothelial cells, and
podocytes. Both mRNA and protein expression for IP receptor
was observable in Tamm-Horsfall-negative distal tubules and
collecting ducts.
Conclusions. The vascular expression of the IP receptor is
consistent with the known vasodilatory effect of prostacyclin in
vascular beds. Glomerular expression argues for a role of this
autacoid in the regulation of glomerular hemodynamics. The
tubular distribution might point towards the involvement of
prostacyclin in renal salt and water handling.
Prostacyclin (PGI2) is a labile metabolite of arachidonic
acid produced by the cyclooxygenase pathway. The actions
of this and other prostanoids are mediated via specific cell
surface receptors that are members of the G protein-
coupled receptor gene superfamily. The human prostacy-
clin receptor (IP receptor) has recently been cloned and
sequenced by us and others [1, 2]. Among human tissues
Northern analysis showed highest expression of IP receptor
mRNA in kidney, arguing for an important role of prosta-
cyclin in renal physiology. PGI2 accounts for elevation of
cAMP concentration in target cells. Consistent with well
characterized pharmacological studies [3] the transient
expression of the IP receptor in COS-M6 cells resulted in
an increase in intracellular cAMP levels upon a challenge
with the stable prostacyclin analog, iloprost. Interestingly,
recent works provided some pharmacological evidence for
the existence of additional IP receptor subtypes in rabbit
kidney and in mast cells, whose activation are presumably
not linked to an increase in cAMP generation [4, 5].
However, the existence of these subtypes awaits confirma-
tion at the molecular level.
PGI2 plays a major physiological role in systemic circu-
lation as a potent mediator of vasodilation and inhibitor of
platelet aggregation. In a recent study we have demon-
strated the intrarenal expression of prostacyclin synthase in
vessels and intraglomerularly in mesangial and endothelial
cells [6]. The effects of prostacyclin on renal functions,
however, are less well understood. In humans the impor-
tance of renal prostaglandins becomes evident upon treat-
ment with nonsteroidal anti-inflammatory drugs (NSAID).
NSAID, which inhibit cyclooxygenase and therefore block
prostaglandin synthesis, can precipitate renal failure in
susceptible individuals [7]. This is probably due to inhibi-
tion of vasodilatory prostaglandins, such as PGI2 and
PGE2. Furthermore, various studies analyzed the interac-
tion between PGI2 and the renin-angiotensin system. PGI2
synthesis is thought to be stimulated by a decrease in
glomerular perfusion pressure in parallel with an increase
in renin secretion [8], and this interaction has been termed
intrarenal baroreceptor pathway [9]. It is thought to coun-
teract the vasoconstrictive effects of angiotensin II on
glomerular perfusion. However, a recent study of Oida and
coworkers failed to demonstrate glomerular expression of
the IP receptor in mouse kidney [10]. Other potential roles
for PGI2 include regulation of arginine vasopressin (AVP)-
induced Na1 absorption in cortical collecting ducts [5],
regulation of water flow [11] and stimulation of matrix
synthesis [12].
Our study was designed to identify the intrarenal target
of PGI2. By means of immunohistology and non-radioac-
tive in situ hybridization, we examined the intrarenal dis-
tribution of the IP receptor in human kidney.
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Monoclonal antibodies directed against von Willebrand-
antigen, and polyclonal antibodies against Tamm-Horsfall
and cytokeratin were purchased from Boehringer/Mann-
heim and Genzyme (Germany), antibodies to smooth mus-
cle cell actin were obtained from Sigma (Germany). Sec-
ondary antibodies were obtained from Dako A/S
(Denmark) and Dianova (Germany). Polyclonal antibodies
against the IP receptor were gained by the immunization
with the peptide RNLTYVRGSVGPAT, located at the
N-terminus of the receptor protein, which was synthesized
onto a lysine matrix. The immune serum was affinity
purified using the lysine coupled peptide. The specificity of
the polyclonal anti-IP receptor antibody was demonstrated
by the following control experiments: (1) no staining was
observed using the preimmune serum; (2) the specificity of
the labeling obtained in kidney sections was controlled by
coincubation of the IP receptor antibodies with an excess of
the synthetic peptide used to produce the antibodies; (3)
Western blot analysis using human platelets revealed a
single band with a molecular weight of approximately 52
kD as determined by SDS-PAGE analysis.
Human kidneys were freshly obtained from tumor ne-
phrectomy surgery. The duration between vascular clamp-
ing of the renal artery and fixation was kept to less than 30
minutes. Immunohistological processing of cryosections
was performed as described by us recently [13]. Briefly,
frozen tissue was cut nominally at 4 mm, thaw-mounted on
poly-L-lysine-coated glass slides, air-dried and fixed in
acetone for 10 minutes at 4°C. The slides were subsequently
incubated 45 minutes at 37°C with the primary antibodies.
Primary antibodies were detected with the alkaline phos-
phatase anti-alkaline phosphatase method or with fluores-
cent secondary antibodies. Immunofluorescence sections
were viewed in a Leitz UV microscope with epi-illumina-
tion using band pass filter combinations for selective red or
green fluorescence.
Generation of cRNA probes
cRNA probes for human IP receptor were prepared as
follows: a 782 bp ApaI - DraII fragment of phIPR1 was
subcloned into pBluescript vector (Stratagene). After lin-
earization of the template DNA with ApaI and EcoRI
antisense and sense cRNA were synthesized and labeled
with digoxigenin using a nonradioactive nucleic acid syn-
thesis kit (Boehringer Mannheim, Germany). The integrity
of the cRNA-probes was determined by electrophoresis
through a 3% polyacrylamide/6 M urea denaturing gel and
ethidium bromide staining. Labeling efficiency of the ribo-
probes was checked by dot blots. To determine the speci-
ficity of the hybridization protocol the following control
experiments were conducted. First, incubation of tissue
sections with RNase prior to hybridization with cRNA-
probe completely prevented staining. Second, we used an
EP3 receptor cRNA probe (kindly provided by A. Schmid)
[14], which is similar in both, length (800 bp) and GC-
content to the IP receptor probe used in this study. The
EP3-probe was run in parallel and resulted in a different
staining pattern that matched with data on EP3 receptor
distribution in kidney presented by Breyer et al [15]. Third,
hybridization with the digoxigenin labeled IP receptor
sense probe was conducted in parallel. No specific staining
reaction was detectable.
In situ hybridization with digoxigenin-labeled probes
In situ hybridization was essentially carried out as de-
scribed previously [13]. Cryostat sections of 4 mm thickness
were cut and fixed for one hour with 4% paraformaldehyde
in PBS, pH 7.2. Sections were treated with 0.2 N HCl,
acetylated in 0.1 M triethanolamine and 0.25% acetic
anhydride, and finally dehydrated in 100% alcohol. Digoxi-
genin-labeled riboprobes (1 ng/ml) were added to the
hybridization solution containing 50% deionized form-
amide, 0.3 M NaCl, 10 mM Tris-HCl, pH 8, 1 mM EDTA,
0.2 mg/ml salmon sperm DNA, 1 mg/ml yeast transfer
RNA, 1 3 Denhardt’s solution, and 10% dextran sulfate
and incubated for 18 hours at 57°C. The slides were washed
sequentially with 1 3 SSC at room temperature for one
hour, 15 minutes in 0.5 3 SSC at 55°C and 10 minutes in
1 3 SSC. The sections were then treated with 20 mg/ml
RNase A (Boehringer, Mannheim, Germany) in 0.5 M
NaCl/10 M Tris-HCl, pH 7.4/1 mM EDTA for 30 minutes at
37°C. Sections were washed 5 3 in 1 3 SSC and were then
equlilibrated in buffer 1 (0.1 M Tris-HCl and 0.15 M NaCl,
pH 7.5) and incubated with buffer 1 containing 2% block-
ing reagent (Boehringer) and 1% BSA (Sigma, Germany)
for 30 minutes at room temperature. The sections were
incubated with alkaline phosphatase-conjugated sheep an-
ti-digoxigenin antibody (Boehringer Mannheim) diluted
1:500 in buffer 1 containing 1% normal sheep serum and
2% blocking reagent for 60 minutes at room temperature.
The slides were washed twice with buffer 1 and rinsed in
buffer 3 (0.1 M Tris-HCl, 0.1 M NaCl, 0.05 M MgCl2, pH
9.75). Then, 9 ml 4-nitro blue tetrazolium chloride, 7 ml
5-bromo-4-chloro-3-indoylphosphate (Boehringer Mann-
heim) and 0.5 mg levamisole (Sigma) in 2 ml of buffer 3
were added. The color reaction was stopped with 0.01 M
Tris-HCl, 1 mM EDTA, pH 8.0. Slides were rinsed with
distilled water and covered with aqueous mounting me-
dium.
RESULTS
Characterization of anti-IP receptor polyclonal
antibodies
We raised a polyclonal antiserum against the hydrophilic
amino terminus of human IP receptor. To assess specificity
of the antibody, we performed Western immunoblot of
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membrane fractions from human platelets. Platelets are
known to express IP receptor for counteracting the
proaggregatory action of thromboxane [16]. As shown in
Figure 1A the anti-IP receptor antibodies identified a
diffuse band with an apparent molecular mass of approx-
imately 52 kD.
Furthermore, the antibody specificity was confirmed by
preabsorption of the purified anti-IP receptor antibodies
prior to immunohistochemistry with an excess of IP peptide
against which they were raised. The labeling was specific as
it could be blocked by preincubation of the antibodies with
the synthetic peptide (Fig. 1 B, C). Coincubation with an
unrelated peptide has had no effect on labeling (data not
shown).
Expression of IP-immunoreactive protein in human
kidney
The regional distribution and cellular localization of IP
receptor protein was investigated in human kidney sections.
In renal cortex IP receptor immunoreactive protein was
most prominent in endothelial cells and smooth muscle
cells of small arteries (Fig. 2A) and veins (data not shown).
A consistent labeling was observed in peritubular capillar-
ies (exemplarily indicated by arrowhead in Fig. 2A). Ex-
pression of IP receptor immunoreactive protein also local-
ized in smooth muscle cells of interlobular arteries (Fig.
2B). In addition to these vascular structures we observed
immunoreactive protein in glomeruli (Fig. 2C). The intra-
glomerular staining pattern observed was diffuse, suggest-
ing that IP receptor protein is expressed in all glomerular
cells, that is, mesangial cells, endothelial cells and visceral
epithelial cells. Staining of podocytes could be identified by
light microscopy.
Furthermore, we observed labeling of tubular epithelial
cells with anti-IP receptor polyclonal antibodies. As judged
by light microscopy we tentatively identified these tubular
structures as distal tubules (Fig. 2D) and cortical collecting
ducts (data not shown). A faint staining was also observed
in medullary collecting duct cells (Fig. 2E). Compared to
the staining of cortical tubules the signals obtained in
medullary tubules were less strong.
Double-immunofluorescence allowed us to colocalize
definitively the IP receptor immunopositivity with von
Willebrand factor in endothelial cells (Fig. 3 A, B). To
identify the specific segment of the distal tubule we per-
formed double-immunofluorescence with anti-Tamm-
Horsfall antibodies. Tamm-Horsfall-protein is known to be
expressed in medullary and cortical thick ascending loops
of Henle [17]. The expression of IP receptor protein was
only present in Tamm-Horsfall-negative distal tubules (Fig.
3 C, D). In renal medulla immunoreactivity towards anti-IP
receptor antibodies was detectable in vasa recta. Colocal-
ization with smooth muscle cell actin allowed the positive
identification of these structures (Fig. 3 E, F).
Expression of IP receptor mRNA in human kidney
To confirm the expression pattern observed with the
anti-IP receptor antibodies, we analyzed expression of IP
receptor mRNA in human kidney cryosections.
In renal cortex processed with IP receptor antisense
riboprobe staining is visible in glomeruli and vascular
structures. In arteries (Fig. 4A) and veins (data not shown),
IP receptor mRNA is expressed in both endothelial and
smooth muscle cells.
In the glomeruli intense staining was observed at the
margins of the glomerular lobules, which suggests an
abundant expression of the IP-receptor mRNA in podo-
cytes (Fig. 4B). In addition a faint staining throughout the
glomerulus was observed. Note that staining was also
detectable in endothelial and smooth muscle cells of the
glomerular arteriole. No staining was found in cells of
macula densa.
Apart from glomeruli and vessels we detected expression
of IP receptor mRNA in cells of the distal tubule (Fig. 4C).
Tubular staining was observed consistently; although stain-
ing was less intense compared to vessels and glomeruli.
These structures could be identified as Tamm-Horsfall
negative distale tubules since serial sections processed for
IP receptor mRNA and Tamm Horsfall protein revealed no
colocalization (data not shown). In renal medulla expres-
sion of IP receptor mRNA was confined to collecting
tubules (Fig. 4D) and vasa recta (Fig. 4E).
DISCUSSION
Western blot analysis
To test the specificity of the affinity purified, polyclonal
anti-human IP receptor antibodies we used two different
approaches: competition immunohistochemistry and West-
ern blot analysis. In immunohistochemistry the staining
could be blocked if the antibodies were preincubated with
the IP receptor peptide. Immunoblotting was performed
using a human platelet membrane fraction. A slightly
diffuse band with an apparent mobility of about 52 kD is
visible, and the molecular weight predicted from the open
reading frame of the human IP receptor cDNA is 41 kD [2].
The deduced amino acid sequence of the IP receptor
displays two potential N-linked glycosylation consensus
sequences (Asn-X-Ser/Thr) at Asn7 and Asn203. A similar
difference between the calculated molecular weight (37
kD) and the observed weight as judged by SDS-PAGE (55
kD) has been reported for the human thromboxane recep-
tor, which contains two N-linked glycosylation sites as well
(Asn4 and Asn16) [18, 19]. Therefore, we speculate that the
discrepancy between the predicted and apparent molecular
weight may be due to glycosylation of the IP receptor
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protein with subsequent alteration of migration on SDS-
PAGE. In summary, these data present strong evidence for
the specificity of the generated IP receptor antibodies.
Vascular expression of the IP receptor
The involvement of PGI2 in renal regulatory mechanisms
are becoming increasingly apparent, but many questions
remain unanswered. An important aspect is the distribution
of the target of PGI2, and thus cells expressing IP receptors.
In human kidney, IP receptor expression was present in
endothelial cells of arteries and veins. We speculate that
PGI2 might act in a feedback manner on endothelial cells to
counteract the action of thromboxane. Human endothelial
cells are known to express the thromboxane receptor [20].
PGI2 and TXA2 have a dominant role in the hemostatic
balance, which involves interaction between platelets and
endothelial cells [21].
Expression in smooth muscle cells, however, was con-
fined to all vascular beds. Identical to mouse kidney, we
observed the expression of both IP receptor mRNA and IP
receptor immunoreactive protein in interlobular arteries
and afferent arterioles. These findings are in agreement
with various studies on renal hemodynamics [22, 23]. In
humans, infusion of prostacyclin resulted in a decrease of
renal vascular resistance and an increase of renal plasma
flow [11]. Moreover, prostaglandins, especially PGI2, have
been shown to antagonize the constrictor action of a variety
of pressure hormones, including angiotensin II and norepi-
nephrine. Furthermore, the expression of the IP receptor in
the vasa recta suggests it has an important role in regulating
renal microcirculation. The relevant target site is thought
to be the renal medulla, thereby protecting the highly
vulnerable medulla against ischemic damage under patho-
physiological conditions.
Glomerular expression of IP receptor
In renal cortex, we observed significant glomerular ex-
pression of both IP receptor immunoreactive protein and
IP receptor mRNA. Double-immunofluorescence revealed
that IP receptor is expressed in all glomerular cell types. In
accordance with its expression in vivo we observed expres-
sion of mRNA for IP receptor in cultured human podocytes
Fig. 1. Specificity of the anti-IP receptor antibody. (A) Western blot analysis of platelets using anti-IP receptor antibodies. Ten percent SDS-PAGE
of platelet proteins showing a diffuse band of about 52 kD are identified by affinity purified anti-IP receptor antibodies. (B) Staining of kidney cortical
section with anti-IP receptor antibodies (magnification 3100). (C) Preabsorption of the anti-IP receptor antibody with an excess of IP receptor peptide
prior to immunostaining (magnification 3100). No or negligible signals are observed. Publication of this figure in color was made possible by a grant
from KfH Kuratorium fu¨r Dialyse und Nierentransplantation e.V., Marburg, Germany.
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as well as in mesangial cells (manuscript in preparation).
These findings are in contrast with data from Oida et al
[10], who observed IP receptor mRNA expression limited
to interlobular arteries and afferent arterioles in mouse
kidney. However, no mRNA expression was detectable in
glomeruli. Apart from technical differences (radioactive vs.
non-radioactive in situ hybridization) the different pattern
of IP receptor expression we observed in human kidney
may reflect the relative abundance of prostacyclin synthase
expression in human glomeruli [24] or glomerular cells
[25]. Although the expression of prostacyclin synthase
has not been analyzed in murine glomeruli, it is worth
mentioning that PGI2 is the main prostanoid in human
glomeruli, in contrast to rodents where PGE2 appears to
be the main metabolite of arachidonic acid [26]. We
detected a low but significant expression of prostacyclin
synthase in glomerular endothelial cells and in mesangial
cells and, consistently, we observed that PGI2 is the main
Fig. 2. Localization of the IP receptor immunoreactive protein in adult
human kidney sections. (A) Expression of IP receptor in a small artery
(magnification 3500). A strong signal can be observed in the smooth
muscle cells. (B) Expression of IP receptor in endothelial and smooth
muscle cells of an interlobular artery (magnification 3400). Note the
absence of immunoreactivity in the adjacent proximal tubules. (C) Kidney
section representing the glomerulus. A diffuse signal was obtained,
indicating that mesangial cells, glomerular endothelial cells and visceral
epithelial cells exhibit reactivity (magnification 3400). (D) In renal
cortical sections anti-IP receptor antibodies stained cells of distal tubuli
(magnification 3400). (E) In renal medullary sections, cells of collecting
tubuli exhibited specific antigenicity towards the anti-IP receptor antibod-
ies (magnification 3250). Publication of this figure in color was made
possible by a grant from KfH Kuratorium fu¨r Dialyse und Nierentrans-
plantation e.V., Marburg, Germany.
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metabolite in human cultured mesangial cells (unpub-
lished observations). In line with our finding of glomer-
ular IP receptor expression, the prostacyclin analog
iloprost has been shown to antagonize the cyclosporine
A-induced constriction in human glomeruli [27]. The consti-
tutive expression of prostacyclin synthase and the IP receptor
probably serves to antagonize signals conveyed tonically by
angiotensin II and other vasoconstritive agents.
Fig. 3. Colocalization of the IP immunoreactive protein with various antigens. Colocalization of IP receptor (A) with von Willebrand factor (B). A
monoclonal antibody directed to von Willebrand factor was used to identify endothelial cells (exemplary indicated by white arrow). No colocalization
of IP receptor (C) with Tamm-Horsfall protein (D). Location of the distal tubule stained by anti-IP receptor antibody is indicated by white arrow. In
this area no expression of Tamm-Horsfall protein is visible. Colocalization of IP receptor (E) with smooth muscle actin (F) in vasa recta (magnification
A-F, 3500).
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Expression of the IP receptor in distal tubule and
collecting duct cells
In contrast to mouse, we observed in human kidney
expression of IP receptor in the distal tubules and in
collecting ducts. To our knowledge this is the first study
providing direct evidence for the expression of IP receptor
protein in human tubular epithelial cells. Although modu-
lation of renal salt and water handling has been mainly
attributed to the tubular actions of prostaglandin E2
(PGE2) via various PGE2 (EP) receptors, some studies
have shown that prostacyclin also exerts direct effects on
the modulation of Na1 absorption and hydraulic conduc-
tivity along the nephron. PGI2 has been shown to be
natriuretic in dogs when infused into the renal artery at low
concentrations [28], and PGI2 inhibits both transepithelial
voltage and Na1 reabsorption in rabbit isolated perfused
cortical collecting ducts [29]. These data were recently
corroborated and extended by Hebert, Regnier and Peter-
son [5]. Apart from the natriuretic effects and inhibition of
the AVP-induced increase of the hydraulic conductivity by
PGI2 in rabbit collecting ducts, the authors demonstrated
that PGI2 signal was not transduced by an increase in
cAMP levels. Instead, activation of phospholipase C and
inhibition of adenylate cyclase activity were observed, and
therefore, the existence of new receptor subtypes was
concluded. Using the PGI2 analogs iloprost and carba-
prostacyclin, the presence of a Gi-coupled PGI2-receptor
was also observed in isolated cells of rat medullary thick
Fig. 4. Localization of IP receptor mRNA in
human kidney sections. (A) Expression of IP
receptor mRNA in a renal artery. Strong
staining of endothelial and smooth muscle cells
is observed. Note absence of staining in
surrounding proximal tubules. (B) Presence of
IP receptor mRNA in a glomerulus. In the
glomerulus strong labeling is observed in
podocytes. In addition, expression of IP
receptor mRNA in endothelial and smooth
muscle cells of a glomerular arteriole (indicated
by arrowhead) is visible. (C) Staining of IP
receptor mRNA is visible in cells of distal
tubule. (D) Staining of IP receptor mRNA is
visible in cells of collecting duct. (E) In renal
medulla a strong signal for IP receptor mRNA
was detected in vasa recta. Note the absence of
staining in the surrounding tubular epithelial
cells (magnification A-E, 3400).
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Fig. 4. Continued.
ascending limbs of Henle [30, 31]. Additionally, recent data
support a role for PGI2 as a mediator of increased distal
tubule HCO3
2 secretion [32]. This effect might be medi-
ated by an increase of intracellular cAMP levels. Our study
did not address the intracellular signal transduction system,
but to our knowledge there is currently no proof for the
existence of IP receptor subtypes at the molecular level.
Concerning the physiological significance of IP receptor
expression in human collecting ducts, the study of Natov
and coworkers is particularly relevant to our findings [11].
Infusion of PGI2 in healthy volunteers with normal kidney
induced a slight, but significant natriuretic effect. Although
it has been largely accepted in the literature that PGI2
induces natriuresis primarily through a decrease in filtra-
tion fraction or through “a washout” of the corticopapillary
gradient by enhanced medullary blood flow, a decrease in
filtration fraction has not been consistently followed by a
rise in natriuresis [33]. In this regard, a direct effect of PGI2
via a tubular IP receptor may account for the observed
natriuresis.
In summary, we found prominent expression of IP
receptor immunoreactive protein and mRNA in endothe-
lial cells, glomeruli and in smooth muscle cells of interlob-
ular arteries, afferent arterioles and small veins. These
findings are in agreement with numerous physiological
studies analyzing the effects of prostacyclin infusion on
renal hemodynamics and glomerular perfusion. Although
direct effects of prostacyclin on renal salt and water
handling have already been described in the rabbit cortical
collecting duct, and in vivo effects of prostacyclin in humans
are compatible with our findings, the expression of IP
receptor protein and mRNA in distal tubules and collecting
ducts points towards new functions of PGI2 in human
kidney that are currently poorly defined. Further work is
needed to unravel the physiological significance of prosta-
cyclin on renal salt and water handling in humans, and to
clarify the signal transduction systems involved.
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APPENDIX
Abbreviations used in this article are: AVP, arginine vasopressin; COX,
cyclooxygenase; EP receptor, prostaglandin E2 receptor; GFR, glomerular
filtration rate; IP receptor, prostacyclin receptor; NSAID, nonsteroidal
antiinflammatory drug; PGE2, prostaglandin E2; PGI2, prostacyclin; RT-
PCR, reverse transcriptase-polymerase chain reaction; TXA2, thrombox-
ane A2.
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